ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2651

Vasculitis Associated with VEXAS Syndrome

Megan Sullivan1, Kambiz Kalantari2, Carolyn Mead-Harvey3, Yael Kusne4, Mrinal Patnaik2, Abhishek Mangaonkar2, Ronald Go2, Daniel Montes2, Kaaren Reichard2, Horatiu Olteanu2, Melanie Bois2, Alexander Hines2, Julio Sartori-Valinotti5, Kenneth Warrington2 and Matthew Koster2, 1Mayo Clinic Arizona, Scottsdale, AZ, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Scottsdale, AZ, 4Mayo Clinic, Phoenix, AZ, 5Mayo Clinic, Rohester, MN

Meeting: ACR Convergence 2024

Keywords: ANCA associated vasculitis, Autoinflammatory diseases, giant cell arteritis, Vasculitis, Vasculitis, Cutaneous

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently defined clinical entity that causes hematologic and autoinflammatory symptoms. Since its initial description in 2020, it was recognized to mimic many other rheumatologic conditions. For example, in the incident VEXAS cohort of 25 patients described by Beck and colleagues, 60% had been diagnosed with relapsing polychondritis, 12% with polyarteritis nodosa, and 4% with giant cell arteritis (1).  Our objective is to define the prevalence, distribution, and characteristics of vasculitis in a cohort of patients with VEXAS syndrome.

Methods: Patients with VEXAS syndrome, verified by positive UBA1 mutation, were included. Chart review was performed to identify patient characteristics and outcomes. Vasculitis diagnosis was based on either histopathology showing vascular inflammation or non-invasive angiography findings. Summary statistics were calculated.

Results: Eighty-one patients met inclusion criteria. All were male with a median age of onset of 66.9 years (IQR 60.1, 72.7).  Median (IQR) follow up was 4.0 (2.2-5.4) years during which 22 patients (27.2%) had histopathology or non-invasive angiography positive for vascular inflammation. Vasculitis subtypes included cutaneous small vessel vasculitis (16/81 19.8%), ANCA-associated vasculitis (2.5%), cutaneous medium vessel vasculitis (2.5%), and large vessel vasculitis (2.5%). No patient had more than one vessel size involved. Histopathology in small vessel vasculitis patients was consistent with cutaneous leukocytoclastic vasculitis in the majority (Figure 1). One patient had leukocytoclastic peritubular capillaritis on renal biopsy. Cranial symptoms (headache, vision changes, or jaw pain) were noted in 16 (19.8%). Two patients exhibited large vessel involvement with confirmed carotid thickening on non-invasive angiography; one of these had a positive temporal artery biopsy revealing an unusual pattern of focal endothelialitis consisting of mixed inflammatory infiltrate and neutrophils (Figure 2). Disease characteristics did not differ between those with cutaneous small vessel vasculitis to those without (Table 1).

Conclusion: VEXAS syndrome manifests as a variable vessel vasculitis in a quarter of patients, with cutaneous small and medium vessel involvement being particularly common. Some patients may have positive ANCA serologies or even renal leukocytoclastic vasculitis leading to misdiagnosis. Cranial symptoms are common and may mimic giant cell arteritis, though documented large vessel inflammation is rare.

Supporting image 1

Figure 1. Small vessel vasculitis in VEXAS syndrome. (A) Gross image of petechial rash in a patient with VEXAS syndrome. (B) Pathology from above patient with sparse neutrophilic inflammation surrounding superficial dermal blood vessel walls consistent with small vessel vasculitis.

Supporting image 2

Figure 2. Large vessel vasculitis in VEXAS syndrome. (A) Left internal (solid arrow) and external (dashed arrow) carotid circumferential periarterial thickening on computed tomography angiography in a patient with VEXAS syndrome. (B) Temporal artery biopsy at low power (40x original magnification, hematoxylin and eosin stain) showing non-specific chronic inflammation around the periadventitial vessels (arrow) and endothelialitis with mixed inflammation is present in the intima of a muscular temporal artery 200x original magnification (enlarged image), hematoxylin and eosin stain.

Supporting image 3

Table 1. Characteristics of VEXAS patients with and without cutaneous small vessel vasculitis. 1Wilcoxon rank sum p-value; 2Fisher Exact p-value;


Disclosures: M. Sullivan: None; K. Kalantari: None; C. Mead-Harvey: None; Y. Kusne: None; M. Patnaik: StemLine, 5; A. Mangaonkar: Bristol-Myers Squibb(BMS), 5, Incyte, 5, Novartis, 5; R. Go: None; D. Montes: None; K. Reichard: None; H. Olteanu: None; M. Bois: None; A. Hines: None; J. Sartori-Valinotti: None; K. Warrington: Amgen, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 5, sanofi, 2; M. Koster: Amgen, 1.

To cite this abstract in AMA style:

Sullivan M, Kalantari K, Mead-Harvey C, Kusne Y, Patnaik M, Mangaonkar A, Go R, Montes D, Reichard K, Olteanu H, Bois M, Hines A, Sartori-Valinotti J, Warrington K, Koster M. Vasculitis Associated with VEXAS Syndrome [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/vasculitis-associated-with-vexas-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vasculitis-associated-with-vexas-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology